ClinicalTrials.gg
RecruitingNCT06916793Updated Sep 3, 2026

A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

A Phase 3 interventional study of CKD-843 dose#1 and CKD-843 dose#2 in Androgenetic Alopecia, sponsored by Chong Kun Dang Pharmaceutical. Recruiting at 1 site in South Korea. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Chong Kun Dang Pharmaceutical · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Alopecia with a site in Korea, Republic of — 5 open to participants now, 5 under way, 3 of them phase 3. Alopecia · Korea, Republic of.

Planned enrollment
5th of 21
288 · median 80
Started
2025
with 1 other
Phase 3
6 of 22
3 open now
Registered
19th of 22
by date
Lead sponsor
4 of 22
Chong Kun Dang Pharmaceutical

Among the 22 studies in Alopecia with a site in Korea, Republic of, this one is the 5th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 3, and was the 19th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

5 of the 22 studies in Alopecia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 50 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Alopecia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia

Read the detailed description

The participants were randomly assigned to one of the following groups: CKD-843 dose #1, CKD-843 dose #2, placebo, or Dutasteride group. They received the assigned medication, placebo for blinding, or the reference drug over a 12-month period.

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male of age 18-50 years
  • Clinical Diagnosis of Androgenetic Alopecia
  • Written

Key Exclusion Criteria:

  • Other types of Alopecia or other diseases that can cause hair loss
  • scalp disease such as seborrheic dermatitis or psoriasis
  • Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator
  • Participants who do not agree to use during the trial and for 24 weeks after the last dose, and plan to provide sperm or conceive within 24 weeks after the last dose
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
288 participants (estimated)

Study arms

  • Experimental
    Test Group1

    CKD-843 dose#1 + Placebo of Dutasteride Capsule

    Drug: CKD-843 dose#1 · Drug: Placebo of Dutasteride Capsule

  • Experimental
    Test Group2

    CKD-843 dose#2 + Placebo of Dutasteride Capsule

    Drug: CKD-843 dose#2 · Drug: Placebo of Dutasteride Capsule

  • Placebo comparator
    Placebo-controlled Group

    Placebo of CKD-843 dose + Placebo of Dutasteride Capsule

    Drug: Placebo of CKD-843 dose · Drug: Placebo of Dutasteride Capsule

  • Active comparator
    Active-controlled Group

    Placebo of CKD-843 dose + Dutasteride Capsules

    Drug: Placebo of CKD-843 dose · Drug: Dutasteride Capsules

Interventions

  • IM injection every 3 months for 12 months

  • IM injection every 3 months for 12 months

  • DrugPlacebo of CKD-843 dose

    IM injection every 3 months for 12 months

  • oral, once daily, 12 months

  • DrugPlacebo of Dutasteride Capsule

    oral, once daily, 12 months

06

What researchers measure

Primary outcomes

  1. Total number of hair Changes

    from Baseline at Week24 of total number of hair changes

    Time frame: Baseline, Week 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 29 months after the start.

Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 8, 2025
StartActual
Apr 8, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06916793
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Apr 8, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Sep 3, 2026

Study contacts

OhSang Kwon, MD, PhD
Contact
oskwon@snu.ac.kr
+2-2072-2417
OhSang Kwon, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CKD-843

Start the discussion